MedTrace Logo

Urine CXCL10 Monitoring Trial in Kidney Transplant

NCT03206801 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2026-05-05

No results posted yet for this study

Summary

This is a Phase II-III multi-center prospective randomized controlled clinical trial of incident adult renal transplant patients.

The primary objective of this study is to determine if the early treatment of rejection, as detected by urinary CXCL10, will improve renal allograft outcomes.

Conditions

  • Kidney Transplant; Complications
  • Rejection of Renal Transplant

Interventions

PROCEDURE

Kidney transplant biopsy

Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Canadian National Transplant Research Program

    collaborator OTHER

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Julie Ho, MD · University of Manitoba

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-03
Primary Completion
2025-06-06
Completion
2025-09-26

Countries

  • Australia
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03206801 on ClinicalTrials.gov